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Abstract
Aims This study aimed to assess the utility of contemporary clinical risk scores and explore the ability of two biomarkers
[growth differentiation factor-15 (GDF-15) and soluble ST2 (sST2)] to improve risk prediction in elderly patients with cardio-
genic shock.
Methods and results Patients (n = 219) from the multicentre CardShock study were grouped according to age (elderly
≥75 years and younger). Characteristics, management, and outcome between the groups were compared. The ability of the
CardShock risk score and the IABP-SHOCK II score to predict in-hospital mortality and the additional value of GDF-15 and
sST2 to improve risk prediction in the elderly was evaluated. The elderly constituted 26% of the patients (n = 56), with a higher
proportion of women (41% vs. 21%, P < 0.05) and more co-morbidities compared with the younger. The primary aetiology of
shock in the elderly was acute coronary syndrome (84%), with high rates of percutaneous coronary intervention (87%).
Compared with the younger, the elderly had higher in-hospital mortality (46% vs. 33%; P = 0.08), but 1 year post-discharge
survival was excellent in both age groups (90% in the elderly vs. 88% in the younger). In the elderly, the risk prediction models
demonstrated an area under the curve of 0.75 for the CardShock risk score and 0.71 for the IABP-SHOCK II score. Incorporating
GDF-15 and sST2 improved discrimination for both risk scores with areas under the curve ranging from 0.78 to 0.84.
Conclusions Elderly patients with cardiogenic shock have higher in-hospital mortality compared with the younger, but
post-discharge outcomes are similar. Contemporary risk scores proved useful for early mortality risk prediction also in the
elderly, and risk stratification could be further improved with biomarkers such as GDF-15 or sST2.
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Introduction
The management of cardiogenic shock (CS) in the
elderly poses a clinical challenge. On one hand, the elderly
are at the highest risk for adverse outcomes and
therefore have the greatest potential to benefit from
treatment, but, on the other hand, they are vulnerable
to treatment-related complications. Furthermore, there
is remarkable individual variation in functional and
cognitive reserves among this age group, presenting a
hurdle to the objective evaluation of the prognosis in acute
settings.
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Early assessment of shock severity is crucial in order to
single out patients at high risk of death. Accurate risk stratifi-
cation could guide the treatment and help in the allocation
of clinical resources, through identification of patients
most likely to benefit from the highly intense and costly treat-
ment options. Age itself elevates the risk of myocardial
infarction-related CS, and advanced age is an additional
known risk factor for CS mortality.1,2 Risk prediction models
have been introduced to facilitate risk assessment and the
prediction of mortality in the acute phase of CS. Two risk pre-
diction scores, the CardShock risk score and the IABP-SHOCK
II score, have been developed specifically for CS and have
shown good performance in both early risk stratification
and prediction of short-term mortality.1,3,4 However, the util-
ity of these risk score models in the elderly remains unclear.
Biomarkers have become significant prognostic tools in many
cardiovascular diseases.5,6 Most recently, growth differentia-
tion factor-15 (GDF-15) and soluble ST2 (sST2) have been
found to be valuable in risk stratification in heart failure
and CS,7–10 but data on elderly patients with CS in the con-
temporary era remain scarce.
We examined the clinical picture, management, and out-
comes of patients aged ≥75 years in a prospective,
multicentre study on CS. Our aim was to compare the key
features between survivors and non-survivors and to assess
the performance of the contemporary risk prediction scores
in the elderly. Finally, we investigated the ability of GDF-15
and sST2 to improve early risk stratification in this age group.
Methods
The CardShock study (NCT01374867 at https://www.
ClinicalTrials.gov is a prospective, observational, multicentre
study on CS, including both acute coronary syndrome
(ACS)-related and non-ACS-related aetiologies. Nine tertiary
hospitals in eight European countries participated between
October 2010 and December 2012, enrolling 219 patients.
The detailed design and the primary results of the study have
been published elsewhere.1
Inclusion criteria and data collection
Besides an acute cardiac cause, the inclusion criteria
consisted of systolic blood pressure <90 mmHg (after
adequate fluid challenge) for 30 min, or need for vasopressor
therapy to maintain systolic blood pressure >90 mmHg, and
signs of hypoperfusion (altered mental status/confusion, cold
periphery, oliguria <0.5 mL/kg/h for the previous 6 h, or
blood lactate >2 mmol/L). The exclusion criterion was shock
caused either by ongoing hemodynamically significant ar-
rhythmias or by cardiac or non-cardiac surgery. Patients had
to be over 18 years old, and they had to be included within
6 h of the identification of the shock.
Baseline characteristics and previous medical history were
recorded. Biochemical and clinical findings, as well as haemo-
dynamic parameters, were documented at detection of shock
and at pre-specified time points until 96 h after inclusion.
Patients were treated according to local practice in each hos-
pital, and treatment procedures were registered. The primary
outcomewas all-cause in-hospital mortality. In addition, 1 year
mortality was assessed. After hospital discharge, three pa-
tients were lost to follow-up. In the mortality analyses, their
cases were censored at the time of hospital discharge. Written
informed consent was obtained from the patient or, according
to local regulations, from a close person or a relative. Vital sta-
tus during follow-up was determined through direct contact
with the patient or next of kin or through population and hos-
pital registers. The study was approved by the following local
ethics committees: Athens: Ethics Committee of Attikon
University Hospital; Barcelona: Health Research Ethics
Committee of the Hospital de Sant Pau; Brescia: Ethics
Committee of the Province of Brescia; Brno: Ethics Committee
of University Hospital Brno; Helsinki: The Ethics Committee,
Department of Medicine, The Hospital District of Helsinki
and Uusimaa; Porto: Ethics Committee of São João Hospital
Center/Porto Medical School; Rome: Ethical Committee
Sant’Andrea Hospital; Warsaw: Local Bioethics Committee of
the Institute of Cardiology; and Copenhagen: the study was
approved by the Danish Protection Agency with reference
number GEH-2014-013 and I-Suite number 02731. The study
was conducted in accordance with the Declaration of Helsinki.
Serial blood sampling was performed at baseline and
thereafter at 12 h intervals up to 48 h, and plasma samples
were stored in aliquots frozen at 80 (70)°C until assayed.
Creatinine, C-reactive protein, high-sensitivity troponin
T (hsTnT), N-terminal pro-B-type natriuretic peptide
(NT-proBNP), and GDF-15 (Roche Diagnostics, Basel,
Switzerland) were analysed centrally at ISLAB (Kuopio,
Finland). sST2 was measured at INSERM UMR-S 942
(Paris, France) using a quantitative sandwich monoclonal
enzyme-linked immunosorbent assay (Presage sST2 Assay;
Critical Diagnostics, San Diego, CA, USA). Arterial blood lac-
tate and pH were analysed locally. Estimated glomerular fil-
tration rate (eGFR) was calculated from creatinine values
using the Chronic Kidney Disease Epidemiology Collaboration
equation.11 Acute kidney injury was defined and staged ac-
cording to the Kidney Disease: Improving Global Outcomes
criteria based on creatinine value.12
Risk prediction models
We assessed the ability of two published risk prediction
models, the CardShock risk score and the IABP-SHOCK II
score, to predict in-hospital mortality in the elderly.
Mortality risk prediction in elderly patients with cardiogenic shock 1399
ESC Heart Failure 2021; 8: 1398–1407
DOI: 10.1002/ehf2.13224
The CardShock risk score consists of seven variables mea-
sured at admission in patients with CS of various aetiologies
(age >75 years; eGFR; blood lactate; confusion on admission;
left ventricular ejection fraction <40%; previous myocardial
infarction or coronary artery bypass grafting; and ACS
aetiology) with a maximum of 9 points. The score categorizes
the patients into low-risk (0–3 points), intermediate-risk (4–5
points), and high-risk (6–9 points) groups.1
The IABP-SHOCK II score is derived from the Intra-aortic
Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) study
in patients with CS due to ACS who are undergoing percutane-
ous coronary intervention (PCI). It consists of six variables (age
>73 years; prior stroke; glucose at admission >10.6 mmol/L;
creatinine at admission>132.6 mmol/L; thrombolysis in myo-
cardial infarction flow grade <3 after PCI; and arterial blood
lactate at admission >5 mmol/L) giving a maximum of 9
points. The patients can be classified according to the points
into low-risk (0–2 points), intermediate-risk (3–4 points), and
high-risk (5–9 points) categories.3
Statistical analysis
We categorized the patients by age into (i) ≥75 years old
(elderly group) and (ii) <75 years old (younger group). Elderly
patients were further compared with respect to their
in-hospital survival status (survivors vs. non-survivors).
Results are presented here as number (n) and percentage
(%); mean with standard deviation (SD); or median with
inter-quartile range, as appropriate. Group comparisons were
performed using the χ2 test and Fisher’s exact test for cate-
gorical variables and Student’s t-test and Mann–Whitney U
test for continuous variables. The Kaplan–Meier method
was used to elucidate the timing of events during 30 day
and 1 year follow-up in relation to age group, and statistical
assessment was performed using the log-rank test.
To assess the ability of the CardShock risk score and
IABP-SHOCK II score to predict in-hospital mortality in the
elderly, and to evaluate the additional value of GDF-15 and
sST2 on the risk prediction models, receiver operating charac-
teristic curve analysis was performed. We used previously
defined cut-off values of the biomarkers (GDF-
15 > 7000 ng/L and sST2 > 500 ng/mL) for this analysis.7,8
The distribution of the elderly patients and observed mortal-
ity within risk categories of both risk prediction models were
calculated. The additional value of the biomarkers in mortal-
ity prediction was assessed via the likelihood ratio test for
nested models. For comparison, the CardShock risk score
was further validated in an external cohort of patients with
CS with unselected aetiology from a single-centre prospective
study. The validation was performed in all patients as well as
separately in the elderly (≥75 years) and the younger
(<75 years) patients. Logistic regression was used to investi-
gate the interaction between age and risk prediction models.
A two-sided P-value<0.05 was regarded as statistically signif-
icant. All statistical analyses were performed with SPSS 22.0
statistical software (IBM Corp., Armonk, NY, USA).
Results
Clinical characteristics, presentation, and
treatment of cardiogenic shock in the elderly
Table 1 outlines the baseline characteristics of the elderly and
the younger patients. The elderly constituted 26% (n = 56) of
the patients, with a mean age of 81 ± 4 years. They were
more frequently female (41% vs. 21%, P = 0.003) and had
more co-morbidities overall, with generalized arteriosclerosis
being particularly high compared with younger patients.
Overall, ACS (81%) was the principal aetiology of shock, and
its frequency did not differ between the age groups.
The two age groups were largely similar with respect to
clinical presentation and biochemical findings, as summarized
in Table 2, except for a few differences. Compared with the
younger group, the elderly were less likely to have sinus
rhythm at baseline, and a higher proportion of them had left
ventricular ejection fraction >40%. The elderly group had
worse renal function (creatinine and eGFR) at admission but
with a similar incidence of acute kidney injury as the younger
patients. Biomarker levels of congestion/cardiac stress
(NT-proBNP) were higher in the elderly, whereas the extent
of myocardial injury as measured by hsTnT did not differ
between the groups [peak hsTnT 3680 (1270–14 281) ng/L
in the elderly vs. 3849 (927–12 585) ng/L in the younger;
P = 0.8]. The extent of coronary artery disease assessed by
coronary angiogram in the elderly (one-vessel disease 20%;
multivessel disease 59%; and left main disease 11%) was
comparable with that of the younger group.
The management of CS, including invasive assessment by
coronary angiography and coronary interventions, mechani-
cal ventilation, and use of vasoactive pharmacotherapy, was
similar between the age groups, as shown in Table 3. The
use of intra-aortic balloon pump was more common in the
younger group (61% vs. 39%, P = 0.004). No differences in
the prescription of antithrombotic medication were observed
between the age groups (data not shown).
Outcomes and comparing elderly survivors and
non-survivors
The elderly had numerically higher in-hospital (46% vs. 33%,
P = 0.08) and 1 year (52% vs. 41%; P = 0.17) mortality.
Kaplan–Meier survival curves for in-hospital mortality for all
patients and 1 year mortality for those surviving hospitaliza-
tion stratified by the age group are shown in Figure 1. Of
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note, among patients discharged alive, 1 year survival was
comparable between the age groups (Figure 1 and Table 3).
Causes of death did not differ between the groups
(Supporting Information, Table S1). In addition, an explor-
atory analysis of the patients with ACS aetiology undergoing
PCI (n = 142) showed no difference in in-hospital (41% vs.
38%, P = 0.7) and 1 year (44% vs. 46%, P = 0.8) mortality rates
between the elderly and the younger groups.
Elderly survivors and non-survivors were largely similar
with respect to age, sex, medical history, and shock aetiology
(Table 1). In contrast, the non-survivors suffered from more
severe shock already at baseline, requiring more intense
respiratory and haemodynamic support, as depicted in Tables
2 and 3. Interestingly, non-survivors had significantly higher
GDF-15 levels compared with survivors (Table 2). Survivors
were more likely to undergo coronary angiogram (93% vs.
65%, P = 0.009). The revascularization rate was, however, still
very high (94% had PCI) among non-survivors undergoing an-
giogram (Table 3).
Performance of risk scores for prediction of
in-hospital mortality in the elderly
Compared with the younger patients, the CardShock and
IABP-SHOCK II risk scores more frequently categorized the
elderly patients into the intermediate-risk and high-risk
groups and less frequently into the low-risk group (Figure
2). Both scores were useful for mortality risk prediction in
the elderly; in the low-risk category, the outcome was
favourable, and the mortality increased with higher risk cate-
gory (Figure 2). The elderly demonstrated a higher CardShock
risk score [5.6 (SD 1.5) vs. 4.0 (1.8); P < 0.001] and
IABP-SHOCK II score [4.8 (SD 1.4) vs. 3.2 (1.4); P < 0.001]
compared with the younger. The difference remained signifi-
cant even after excluding the age variable from the model
[CardShock risk score 4.6 (1.4) vs. 4.0 (1.8); P = 0.01 and
IABP-SHOCK II score 3.8 (1.4) vs. 3.2 (1.4); P = 0.02].
The elderly survivors had a lower risk profile than
non-survivors according to both risk models (CardShock risk
score 4.9 vs. 6.4; P < 0.001 and IABP-SHOCK II 4.4 vs. 5.6;
P = 0.009). While both risk models categorized the majority
of the non-survivors (65% in CardShock risk score and 85%
in IABP-SHOCK II) into the high-risk group, a significant pro-
portion of the elderly survivors were classified as
intermediate-risk patients (Figure 3). Age did not have an
effect on the ability of the CardShock risk score or the
IABP-SHOCK II score to predict outcome (Pinteraction 0.82 and
0.47, respectively).
Among the elderly, the CardShock risk score had an area
under the curve (AUC) of 0.75 (vs. 0.82 in the younger group)
and the IABP-SHOCK II score an AUC of 0.71 (vs. 0.73 in the
younger group) for prediction of in-hospital mortality. Each
of the biomarkers increased the discrimination of both the
CardShock and IABP-SHOCK II risk scores (Table 4). Adding
the combination of GDF-15 and sST2 to the risk prediction
models did not improve discrimination compared with adding
only one biomarker at a time (Table 4).
For comparison, the CardShock risk score had an AUC of
0.75 [95% confidence interval (CI) 0.69–0.80] for all patients
(n = 262), 0.77 (95% CI 0.67–0.87) for patients ≥75 years
old (n = 83), and 0.75 (95% CI 0.68–0.82) for patients
<75 years old (n = 179) for predicting in-hospital mortality
in the validation cohort.
Table 1 Clinical characteristics, medical history, and shock aetiology
≥75 years <75 years Elderly survivors Elderly non-survivors
n = 56 (26%) n = 163 (74%) P-value n = 30 (54%) n = 26 (46%) P-value






81 (5) 81 (4) 0.7
Female, n (%) 23 (41) 34 (21) 0.003 13 (43) 10 (39) 0.6
BMI (kg/m2) 26 (5) 27 (4) 0.2 26 (5) 26 (4) 0.9
Resuscitated, n (%) 16 (29) 46 (28) 1.0 7 (23) 9 (35) 0.4
Medical history, n (%)
Hypertension 39 (70) 93 (57) 0.10 21 (70) 18 (69) 1.0
Diabetes 17 (30) 44 (27) 0.6 8 (27) 9 (35) 0.5
History of MI/CABG 19 (34) 38 (23) 0.12 7 (23) 12 (46) 0.07
Prior stroke/TIA 8 (14) 12 (7) 0.12 4 (13) 4 (15) 1.0
PAD 11 (20) 10 (6) 0.003 3 (10) 8 (31) 0.05
Chronic heart failure 7 (13) 29 (18) 0.4 2 (7) 5 (19) 0.2
History of AF 11 (20) 21 (13) 0.2 4 (13) 7 (27) 0.2
Renal insufficiency 11 (20) 14 (9) 0.03 4 (13) 7 (27) 0.2
Smoking history 24 (43) 111 (68) <0.001 14 (47) 10 (39) 0.6
Shock aetiology, n (%)
ACS 47 (84) 130 (80) 0.5 25 (83) 22 (85) 1.0
STEMI 37 (66) 112 (69) 0.7 21 (70) 16 (62) 0.5
ACS, acute coronary syndrome; AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass grafting; MI, myocardial infarc-
tion; PAD, peripheral artery disease; STEMI, ST-elevation myocardial infarction; TIA, transient ischaemic attack.
Data are presented as numbers and percentages (%), means (SD), and median (inter-quartile range).
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Discussion
Within this prospective, multicentre study on CS with unse-
lected aetiology, the elderly constituted one-fourth of the
population. They had a higher in-hospital mortality rate com-
pared with the younger, despite active revascularization.
However, those surviving to hospital discharge had a
favourable long-term prognosis. Contemporary CS risk predic-
tion scores showed good ability for mortality risk stratifica-
tion also in the elderly. The discriminative performance of
the scores could be further improved by biomarkers such as
GDF-15 and sST2.
The elderly constituted 26% of the patients with CS in this
study. In prior studies, the proportion of the elderly has var-
ied between 29% and 37%.2,13,14 In our study, both the clini-
cal presentation and management strategies were similar in
the elderly and the younger patients with CS. Considering
the predominance of ACS aetiology also in the elderly, the
PCI rate was very reasonable; indeed, it was higher than in
previous studies. The PCI rate among the elderly patients
with CS in previous studies varied between 26% and 51% de-
pending on the study period and the study design including
hospital facilities.2,14 The elderly had 40% higher in-hospital
mortality compared with the younger. However, the outcome
at 1 year in the elderly hospital survivors was surprisingly
good and comparable with the younger. Other studies have
reported similar rates of short-term and 1 year mortality in
the elderly.2,13,15
All the centres in our study were tertiary hospitals with an
on-site catheterization laboratory, which might have had an
influence on patient profiles. The most frail elderly patients
judged to have poor prognosis may not have been trans-
ferred to tertiary centres. Consequently, mortality in all
elderly patients may be higher than we found in our study.
The decision whether to transfer the patient or not is made
by the physician in charge, often based on the patient’s clin-
ical condition.
Accurate risk prediction is essential in the critically ill and
in the elderly in particular. Considering the complex patho-
physiology and clinical picture of CS especially in the elderly,
tools for objective risk stratification are needed to help treat-
ment decisions at all levels of care. The favourable prognosis
in discharged elderly patients with CS highlights the impor-
tance of well-balanced treatment decisions early during the
in-hospital phase. We evaluated two contemporary risk
scores developed specifically in CS and found satisfactory
performance in the elderly. Both scores have recently been
externally validated in patients with CS.4,16,17 Furthermore,
according to our additional validation, CardShock risk score
performed well in the elderly in the study population cohort
as well. The risk scores are easy to use, and they can be ap-
plied early in the management of patients with CS. These risk
scores could serve as useful tools for clinicians taking care of
elderly patients with CS in their daily practice. In addition,
they provide objective risk stratification and may therefore
be an aid in allocating resources adequately.
In the current study, the discriminative ability of the risk
scores was, however, somewhat lower in the elderly com-
pared with the younger. Age is included as a variable in both
scores, and certain other variables, such as renal function and
Table 3 Treatment of the shock, length of hospital stay, and outcomes
≥75 years <75 years Elderly survivors Elderly non-survivors
n = 56 (26%) n = 163 (74%) P-value n = 30 (54%) n = 26 (46%) P-value
Treatment, n (%)
Angiogram 45 (80) 137 (84) 0.2 28 (93) 17 (65) 0.009
PCIa 39 (87) 110 (80) 0.3 23 (82) 16 (94) 0.2
TIMI flow <3 prior PCI (n = 167) 38 (95) 114 (90) 0.5 22 (92) 15 (100) 0.5
CABGa 1 (2) 8 (6) 0.5 1 (4) 0 —
IABP 22 (39) 100 (61) 0.004 10 (33) 12 (46) 0.3
Invasive mechanical ventilation 31 (55) 106 (65) 0.2 11 (37) 20 (77) 0.003
Use of vasoactive medication, n (%)
Noradrenaline 40 (71) 124 (76) 0.5 19 (63) 21 (81) 0.15
Dobutamine 25 (45) 84 (52) 0.4 10 (33) 15 (58) 0.07
Adrenaline 13 (23) 33 (20) 0.6 3 (10) 10 (39) 0.01
Levosimendan 12 (21) 41 (25) 0.6 7 (23) 5 (19) 0.7
Outcomes
Incidence of AKI, n (%) (n = 154) 15 (36) 32 (29) 0.4 1 (4) 14 (74) <0.001
Length of hospital stay (days)b 10 (5–18) 14 (8–27) 0.07
In-hospital mortality, n (%) 26 (46) 54 (33) 0.08
One year mortality (n = 216), n (%) 29 (52) 67 (41) 0.17
One year mortality (among hospital
survivors, n = 139), n (%)
3 (10) 13 (12) 1.0
AKI, acute kidney injury; CABG, coronary artery bypass grafting; IABP, intra-aortic balloon pump; PCI, percutaneous coronary angiogram;
TIMI, thrombolysis in myocardial infarction flow.
Data are presented as numbers and percentages (%), means (SD), and median (inter-quartile range).
aProportion of those who underwent angiogram.
bReported only for those who survived to hospital discharge.
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prior manifestation of atherosclerosis, reflect the greater un-
derlying burden of diseases in the elderly. Consequently,
most elderly patients are classified into intermediate-risk or
high-risk groups. Although the majority of the non-survivors
were appropriately categorized as high risk, many elderly sur-
vivors were in the intermediate-risk group, leaving room for
improved risk classification.
We found that incorporating biomarkers into the risk
prediction improved mortality risk discrimination in the
elderly. Considering the complex pathophysiology of CS bio-
markers such as GDF-15, a marker of oxidative stress and as-
sociating with biomarkers of hypoperfusion in CS,8 and sST2,
a marker of cardiac stress and inflammation,18 likely provide
additional prognostic information related to CS that is not
captured by traditional risk score variables, which could be
particularly useful in the elderly. In view of the ageing popu-
lation, more studies on accurate risk stratification and the
optimal management of elderly patients with CS seem
warranted.
Limitations
There are some limitations to be acknowledged. First,
although the number of the patients in the prospective
CardShock study was reasonable, the proportion of elderly
was limited, creating some statistical uncertainty in
between-group comparisons. This is a common problem for
Figure 1 Survival in patients with cardiogenic shock by the age group.
Kaplan–Meier survival curves for all-cause mortality in the elderly
(≥75 years old) (dashed line) and the younger (<75 years old) (solid line)
patients with cardiogenic shock. (A) In-hospital mortality (46% in the el-
derly and 33% in the younger) for all patients. (B) One year mortality
(10% in the elderly and 12% in the younger) for those surviving
hospitalization.
Figure 2 In-hospital mortality by the risk categories in the elderly and
the younger with cardiogenic shock. Distribution of the patients (%; bars)
and in-hospital mortality (%, dashed lines) according to the risk category
(low, intermediate, and high) in the elderly (≥75 years) and in the youn-
ger (<75 years) patients with cardiogenic shock in (A) CardShock risk
score and (B) IABP-SHOCK II score.
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most studies in CS.19 Nevertheless, only a small number of
patients were included in the analyses of the risk scores’ per-
formance and biomarkers. The number of the patients
available differed between the CardShock and the
IABP-SHOCK II risk scores. This is mostly due to the variable
thrombolysis in myocardial infarction flow in the
IABP-SHOCK II score, which was missing in patients who did
not undergo coronary angiogram (e.g. non-ACS aetiology).
Only a few patients were excluded for other missing vari-
ables. Furthermore, GDF-15 and sST2 concentrations were
not available from all patients limiting the number of the
patients included in the analyses assessing the additional
prognostic value of the biomarkers. Secondly, age is one of
the variables in both scores giving one point to the elderly au-
tomatically. This may contribute to higher score levels and
lesser dispersion of the scores among the elderly potentially
diminishing the predictive capability of the risk models.
Thirdly, having been developed in this study population
(patients with CS with different aetiologies), CardShock risk
score will perform better in this patient population compared
with IABP-SHOCK II score, which was developed in a different
patient population (patients with CS due to ACS). Neverthe-
less, IABP-SHOCK II score performed well in this study popu-
lation as well. Finally, all treatment decisions were at the
discretion of the physician in charge. Nevertheless, this study
reflects real-life practice in European tertiary care hospitals,
and the choice of treatment strategy was made after careful
evaluation based on each individual patient’s global health
and clinical presentation.
Conclusions
A quarter of patients with CS are elderly. Despite being simi-
lar to younger patients in terms of clinical presentation and
active revascularization, elderly patients have a higher
in-hospital mortality rate. Those surviving to hospital dis-
charge, however, were comparable with younger discharges
in having a good long-term prognosis. Contemporary mortal-
ity risk prediction scores are useful for risk stratification also
in the elderly. The added value of biomarker-based risk
Figure 3 Elderly survivors and non-survivors and the risk model catego-
ries. Distribution (%) of the elderly (≥75 years) in-hospital survivors and
non-survivors in different risk categories in (A) CardShock risk score
(n = 53) and (B) IABP-SHOCK II score (n = 33). Numbers above the bars
indicate the number of the patients in each category.
Table 4 AUC for the CardShock risk score and for the IABP-SHOCK II score in combination with GDF-15 or sST2 or both biomarkers to
discriminate between in-hospital survivors and non-survivors in the elderly (≥75 years old) and in the younger (<75 years old)
≥75 years <75 years
Model AUC (95% CI) χ2a Pa AUC (95% CI) χ2a Pa
CardShock risk score 0.75 (0.60–0.91) (n = 40) 0.82 (0.74–0.90) (n = 106)
+GDF-15 0.82 (0.69–0.95) 4.92 0.03 0.85 (0.78–0.92) 4.67 0.03
+sST2 0.80 (0.66–0.93) 2.56 0.1 0.83 (0.76–0.91) 1.08 0.3
+GDF-15 + sST2 0.81 (0.68–0.94) 5.76 0.06 0.85 (0.78–0.93) 4.76 0.09
IABP-SHOCK II score 0.71 (0.47–0.94) (n = 28) 0.73 (0.61–0.84) (n = 81)
+GDF-15 0.84 (0.69–0.99) 8.78 0.003 0.81 (0.71–0.90) 8.64 0.003
+sST2 0.78 (0.59–0.96) 5.14 0.02 0.79 (0.69–0.89) 4.75 0.03
+GDF-15 + sST2 0.83 (0.68–0.98) 9.56 0.008 0.81 (0.72–0.90) 9.42 0.009
AUC, area under the curve; CI, confidence interval; GDF-15, growth differentiation factor-15; sST2, soluble ST2.
aχ2 and P-values are shown for comparison of nested models.
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stratification in elderly patients with CS needs to be con-
firmed in larger, prospective cohorts.
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